3PP - Innovative preclinical drug testing platform based on 3D bioprinting culture plates
It is based on the development of 3D printing and electrospinning technology to facilitate the study of cancerous cells in breast tumors.
The aim of the research is to advance personalized medicine to treat one of the most aggressive cancer variants, triple negative, by developing a technology platform through 3D printing that combines for the first time additive manufacturing by filament extrusion and electrospinning. The aim is to nimbly produce 3D printed structures where the patient’s own triple-negative breast cancer cells (tumoroids) are cultured and grown, more effectively mimicking the real conditions of the disease. Thus, it is possible to quickly test the drugs for the seva cure, it is the selection process of the ideal drug much faster and avoiding there is a process of trial and error that currently conditions the possibilities of survival of the patients. The project is expected to have a high clinical-translational impact, which could represent a significant advancement in the development of new preclinical personalized medicine strategies.
Project reference: PLEC2021-007523
Program and call: This project is funded by the Ministry of Science and Innovation under the call for R&D&i projects in strategic lines, in public-private collaboration, of the State Program for R&D&i Addressed to Societal Challenges.
Participants: UdG, CIM UPC, and BCN3D, S.L.
